{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:32:22Z","timestamp":1781670742182,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,4,5]],"date-time":"2011-04-05T00:00:00Z","timestamp":1301961600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1038\/nrclinonc.2011.42","type":"journal-article","created":{"date-parts":[[2011,4,5]],"date-time":"2011-04-05T18:20:29Z","timestamp":1302027629000},"page":"302-306","source":"Crossref","is-referenced-by-count":104,"title":["Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer"],"prefix":"10.1038","volume":"8","author":[{"given":"Martin D.","family":"Forster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin J.","family":"Dedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Frentzas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Kristeleit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Ashworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Poole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Weigelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan B.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Rhoda","family":"Molife","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,4,5]]},"reference":[{"key":"BFnrclinonc201142_CR1","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/nrc1457","volume":"4","author":"N Turner","year":"2004","unstructured":"Turner, N., Tutt, A. & Ashworth, A. Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer 4, 814\u2013819 (2004).","journal-title":"Nat. Rev. Cancer"},{"issue":"Suppl","key":"BFnrclinonc201142_CR2","doi-asserted-by":"publisher","first-page":"a2599","DOI":"10.1200\/jco.2010.28.15_suppl.2599","volume":"28","author":"LR Molife","year":"2010","unstructured":"Molife, L. R.  et al. A phase I study to determine the comparative bioavailability of two different oral formulations of the PARP inhibitor, olaparib (AZD2281), in patients with advanced solid tumors [abstract]. J. Clin. Oncol. 28 (Suppl.), a2599 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201142_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse, P.  et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92, 205\u2013216 (2000).","journal-title":"Cancer Inst."},{"key":"BFnrclinonc201142_CR4","first-page":"pe39","volume":"3","author":"L He","year":"2010","unstructured":"He, L. Posttranscriptional regulation of PTEN dosage by noncoding RNAs. Sci. Signal 3, pe39 (2010).","journal-title":"Sci. Signal"},{"key":"BFnrclinonc201142_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.cell.2008.04.013","volume":"133","author":"L Salmena","year":"2008","unstructured":"Salmena, L., Carracedo, A. & Pandolfi, P. P. Tenets of PTEN tumor suppression. Cell 133, 403\u2013414 (2008).","journal-title":"Cell"},{"key":"BFnrclinonc201142_CR6","first-page":"22","volume":"91","author":"HB Salvesen","year":"2001","unstructured":"Salvesen, H. B.  et al. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int. J. Cancer 91, 22\u201326 (2001).","journal-title":"J. Cancer"},{"key":"BFnrclinonc201142_CR7","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/(SICI)1098-2264(199903)24:3<207::AID-GCC5>3.0.CO;2-3","volume":"24","author":"A Koul","year":"1999","unstructured":"Koul, A., Nilbert, M. & Borg, A. A somatic BRCA2 mutation in RER+ endometrial carcinomas that specifically deletes the amino-terminal transactivation domain. Genes Chromosomes Cancer 24, 207\u2013212 (1999).","journal-title":"Genes Chromosomes Cancer"},{"key":"BFnrclinonc201142_CR8","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","volume":"26","author":"A Ashworth","year":"2008","unstructured":"Ashworth, A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 26, 3785\u20133790 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201142_CR9","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H.  et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921 (2005).","journal-title":"Nature"},{"key":"BFnrclinonc201142_CR10","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1006\/jmbi.2001.4564","volume":"307","author":"C Arnaudeau","year":"2001","unstructured":"Arnaudeau, C., Lundin, C. & Helleday, T. DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells. J. Mol. Biol. 307, 1235\u20131245 (2001).","journal-title":"J. Mol. Biol."},{"key":"BFnrclinonc201142_CR11","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1158\/1078-0432.CCR-06-1269","volume":"12","author":"CJ Lord","year":"2006","unstructured":"Lord, C. J., Garrett, M. D. & Ashworth, A. Targeting the double-strand DNA break repair pathway as a therapeutic strategy. Clin. Cancer Res. 12, 4463\u20134468 (2006).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc201142_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong, P. C.  et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123\u2013134 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201142_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","volume":"376","author":"MW Audeh","year":"2010","unstructured":"Audeh, M. W.  et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376, 245\u2013251 (2010).","journal-title":"Lancet"},{"key":"BFnrclinonc201142_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","volume":"376","author":"A Tutt","year":"2010","unstructured":"Tutt, A.  et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235\u2013244 (2010).","journal-title":"Lancet"},{"issue":"Suppl.","key":"BFnrclinonc201142_CR15","doi-asserted-by":"publisher","first-page":"a3002","DOI":"10.1200\/jco.2010.28.15_suppl.3002","volume":"28","author":"KA Gelmon","year":"2010","unstructured":"Gelmon, K. A.  et al. Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer [abstract]. J. Clin. Oncol. 28 (Suppl.), a3002 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201142_CR16","doi-asserted-by":"publisher","first-page":"53ra75","DOI":"10.1126\/scitranslmed.3001538","volume":"2","author":"KJ Dedes","year":"2010","unstructured":"Dedes, K. J.  et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci. Transl. Med. 2, 53ra75 (2010).","journal-title":"Sci. Transl. Med."},{"key":"BFnrclinonc201142_CR17","doi-asserted-by":"publisher","first-page":"5457","DOI":"10.1158\/0008-5472.CAN-09-4295","volume":"70","author":"B McEllin","year":"2010","unstructured":"McEllin, B.  et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res. 70, 5457\u20135464 (2010).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201142_CR18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/emmm.200900041","volume":"1","author":"AM Mendes-Pereira","year":"2009","unstructured":"Mendes-Pereira, A. M.  et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1, 315\u2013322 (2009).","journal-title":"EMBO Mol. Med."},{"key":"BFnrclinonc201142_CR19","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1126\/science.275.5308.1943","volume":"275","author":"J Li","year":"1997","unstructured":"Li, J.  et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943\u20131947 (1997).","journal-title":"Science"},{"key":"BFnrclinonc201142_CR20","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.4161\/cc.3.10.1164","volume":"3","author":"Y Samuels","year":"2004","unstructured":"Samuels, Y. & Velculescu, V. E. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 3, 1221\u20131224 (2004).","journal-title":"Cell Cycle"},{"key":"BFnrclinonc201142_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0092-8674(00)81780-8","volume":"95","author":"V Stambolic","year":"1998","unstructured":"Stambolic, V.  et al. Negative regulation of PKB\/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95, 29\u201339 (1998).","journal-title":"Cell"},{"key":"BFnrclinonc201142_CR22","doi-asserted-by":"publisher","first-page":"4783","DOI":"10.1200\/JCO.2006.06.7173","volume":"24","author":"JL Hecht","year":"2006","unstructured":"Hecht, J. L. & Mutter, G. L. Molecular and pathologic aspects of endometrial carcinogenesis. J. Clin. Oncol. 24, 4783\u20134791 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201142_CR23","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1093\/jnci\/92.11.924","volume":"92","author":"GL Mutter","year":"2000","unstructured":"Mutter, G. L.  et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J. Natl Cancer Inst. 92, 924\u2013930 (2000).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201142_CR24","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.4161\/cc.8.14.8947","volume":"8","author":"A Gupta","year":"2009","unstructured":"Gupta, A.  et al. Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle 8, 2198\u20132210 (2009).","journal-title":"Cell Cycle"},{"key":"BFnrclinonc201142_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cell.2006.11.042","volume":"128","author":"WH Shen","year":"2007","unstructured":"Shen, W. H.  et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128, 157\u2013170 (2007).","journal-title":"Cell"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2011.42.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2011.42","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2011.42.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:18:56Z","timestamp":1684466336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2011.42"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["BFnrclinonc201142"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2011.42","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,5]]}}}